151 related articles for article (PubMed ID: 36230656)
1. Oncogenic Role of ADAM32 in Hepatoblastoma: A Potential Molecular Target for Therapy.
Fukazawa T; Tanimoto K; Yamaoka E; Kojima M; Kanawa M; Hirohashi N; Hiyama E
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230656
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of ADAM32 with testis-predominant gene expression.
Choi I; Woo JM; Hong S; Jung YK; Kim DH; Cho C
Gene; 2003 Jan; 304():151-62. PubMed ID: 12568724
[TBL] [Abstract][Full Text] [Related]
3. Normal fertility in male mice lacking ADAM32 with testis-specific expression.
Lee S; Hong SH; Cho C
Reprod Biol; 2020 Dec; 20(4):589-594. PubMed ID: 32972883
[TBL] [Abstract][Full Text] [Related]
4. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
5. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity.
Qin T; Li B; Feng X; Fan S; Liu L; Liu D; Mao J; Lu Y; Yang J; Yu X; Zhang Q; Zhang J; Song B; Li M; Li L
J Exp Clin Cancer Res; 2018 Nov; 37(1):287. PubMed ID: 30482232
[TBL] [Abstract][Full Text] [Related]
6. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
7. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
8. A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT).
Hiyama E; Ueda Y; Onitake Y; Kurihara S; Watanabe K; Hishiki T; Tajiri T; Ida K; Yano M; Kondo S; Oue T;
Pediatr Surg Int; 2013 Oct; 29(10):1071-5. PubMed ID: 24026876
[TBL] [Abstract][Full Text] [Related]
9. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
10. Secreted Frizzled Related Protein 2 Modulates Epithelial-Mesenchymal Transition and Stemness via Wnt/β-Catenin Signaling in Choriocarcinoma.
Zeng X; Zhang Y; Xu H; Zhang T; Xue Y; An R
Cell Physiol Biochem; 2018; 50(5):1815-1831. PubMed ID: 30396168
[TBL] [Abstract][Full Text] [Related]
11. DRAM1 regulates the migration and invasion of hepatoblastoma cells via autophagy-EMT pathway.
Chen C; Liang QY; Chen HK; Wu PF; Feng ZY; Ma XM; Wu HR; Zhou GQ
Oncol Lett; 2018 Aug; 16(2):2427-2433. PubMed ID: 30013633
[TBL] [Abstract][Full Text] [Related]
12. IL-6 Promotes Cancer Stemness and Oncogenicity in U2OS and MG-63 Osteosarcoma Cells by Upregulating the OPN-STAT3 Pathway.
Zhang C; Ma K; Li WY
J Cancer; 2019; 10(26):6511-6525. PubMed ID: 31777581
[No Abstract] [Full Text] [Related]
13. Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK Pathway.
Guo J; Guo M; Zheng J
Cancer Manag Res; 2021; 13():773-785. PubMed ID: 33536785
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/β-catenin pathway in esophageal squamous cell carcinoma.
He J; Zhou M; Chen X; Yue D; Yang L; Qin G; Zhang Z; Gao Q; Wang D; Zhang C; Huang L; Wang L; Zhang B; Yu J; Zhang Y
J Exp Clin Cancer Res; 2016 Jun; 35(1):98. PubMed ID: 27329034
[TBL] [Abstract][Full Text] [Related]
16. [SHOX2 promotes migration, invasion and stemness of bladder cancer cells
Zhi X; Zhou J; Tian H; Zhou R; Huang Z; Liu C
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jul; 41(7):995-1001. PubMed ID: 34308848
[TBL] [Abstract][Full Text] [Related]
17. A radiosensitizer, gallotannin-rich extract from Bouea macrophylla seeds, inhibits radiation-induced epithelial-mesenchymal transition in breast cancer cells.
Kantapan J; Paksee S; Duangya A; Sangthong P; Roytrakul S; Krobthong S; Suttana W; Dechsupa N
BMC Complement Med Ther; 2021 Jul; 21(1):189. PubMed ID: 34217266
[TBL] [Abstract][Full Text] [Related]
18. Stemness is Derived from Thyroid Cancer Cells.
Ma R; Bonnefond S; Morshed SA; Latif R; Davies TF
Front Endocrinol (Lausanne); 2014; 5():114. PubMed ID: 25076938
[TBL] [Abstract][Full Text] [Related]
19. OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Qi XK; Han HQ; Zhang HJ; Xu M; Li L; Chen L; Xiang T; Feng QS; Kang T; Qian CN; Cai MY; Tao Q; Zeng YX; Feng L
Theranostics; 2018; 8(8):2202-2216. PubMed ID: 29721073
[No Abstract] [Full Text] [Related]
20. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145.
Ren D; Wang M; Guo W; Zhao X; Tu X; Huang S; Zou X; Peng X
Int J Oncol; 2013 Apr; 42(4):1473-81. PubMed ID: 23404342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
